The ATX-LPA pathway was identified as a regulator of HCC risk in human cirrhosis patients and appears to be an appealing pharmacological target since genetic deletion of Enpp2 ameliorates liver fibrosis, liver steatosis, insulin resistance, glucose intolerance, visceral and subcutaneous adiposity and reduces HCC development in animal models (Figure 4). This evidence concerns the gene ENPP2 and Hepatic fibrosis.